HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Zander, K. Articles by de Leeuw, P. W Search for Related Content PubMed PubMed Citation Articles by van der Zander, K. Articles by de Leeuw, P. W Agricola Articles by van der Zander, K. Articles by de Leeuw, P. W

Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects^1,2,3

¹ From Unilever Food & Health Research Institute, Vlaardingen, Netherlands (KvdZ and MMGK); the Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands (MLB and AAAB); and the Cardiovascular Research Institute Maastricht and Academic Hospital Maastricht, Maastricht, Netherlands (PWdL)

² Supported by Unilever Food & Health Research Institute, Vlaardingen, Netherlands. The test products were provided by the Unilever Food & Health Research Institute.

³ Reprints not available. Address correspondence to PW de Leeuw, Department of Medicine, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands. E-mail: p.deleeuw{at}intmed.unimaas.nl.

Background: Several placebo-controlled clinical studies suggest that products containing isoleucyl-prolyl-proline and valyl-prolyl-proline are able to lower blood pressure without adverse effects. The most efficient way of producing high concentrations of these lactotripeptides (LTPs) is enzymatic hydrolysis of dairy protein (casein) with the use of a mixture of several enzymes derived from the nongenetically modified organism Aspergillus oryzae, including proteases and peptidases. To date, no large studies of the blood pressure–lowering properties of enzymatically produced LTP (ELTP) powder in European populations have been published.

Objective: This study was performed to evaluate the hypothesis that consumption of ELTP in a yogurt beverage for 8 wk significantly lowers blood pressure.

Design: In this multicenter, double-blind, parallel, placebo-controlled trial, office blood pressure was evaluated in 275 Dutch hypertensive subjects. Blood pressures and body weight were measured on several days at baseline and at weeks 4 and 8 of the intervention between 2.5 and 3 h after intake of the test product. Twenty-four–h urine samples were collected at baseline and at the end of the intervention for urinalysis of sodium, potassium, creatinine, and microalbumin excretion.

Results: The results showed that 10.2 mg ELTP/d does not lead to a reduction in systolic blood pressure (P = 0.66) or diastolic blood pressure (P = 0.72) compared with placebo.

Conclusion: This study showed no effect of an ELTP-enriched yogurt beverage on blood pressure in hypertensive subjects in a fairly large study.

This article has been cited by other articles:

				L. A. van Mierlo, M. M. Koning, K. van der Zander, and R. Draijer Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies Am. J. Clinical Nutrition, February 1, 2009; 89(2): 617 - 623. [Abstract] [Full Text] [PDF]